Amrinone stimulation test: Ability to predict improvement in left ventricular ejection fraction after coronary bypass surgery in patients with poor baseline left ventricular function

Journal of the American College of Cardiology

Volumn 28, Issue 6, 1996, Pages 1488-1492

  Perez Baliño, Nestor A ^a   Masoli, Osvaldo H ^a   Meretta, Alejandro H ^a   Rodriguez, Alfredo ^a   Cragnolino, Daniel E ^a   Perrone, Sergio ^a   Boullon, Fernando ^a   Mele, Eduardo ^a   Palacios, Igor ^b   Brown, Kenneth A ^c,d  

^a Anchorena Hospital   (Argentina)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMRINONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROVOCATION TEST;

AGED; AGED, 80 AND OVER; AMRINONE; CARDIOTONIC AGENTS; CORONARY ARTERY BYPASS; CORONARY DISEASE; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; STROKE VOLUME;

EID: 0030588994     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00332-4     Document Type: Article

References (35)

1. 1. Cigarroa CG, DeFillipi CR, Brickner ME, et al. Inotropic contractile reserve during dobutamine stress echocardiography predicts recovery of regional left ventricular function after coronary revascularization. Circulation 1993;88: 430-6.
2. 2. Marzullo P, Parodi O, Reisnhofer B, et al. Value of rest thallium-201/ technetium-99m sestamibi scans and dobutamine echocardiography for detecting myocardial viability. Am J Cardiol 1993;71:166-72.
3. 3. La Canna G, Alfieri O, Giubbini R, Gargano M, Ferrari R, Visioli O. Echocardiography during infusion of dobutamine for identification of reversible dysfunction in patients with chronic coronary artery disease. J Am Coll Cardiol 1994;23:617-26.
4. 201TI single-photon emission computed tomography. Circulation 1995;91:2748-52.
5. 5. Perrone-Filardi P, Pace L, Prastaro M, et al. Dobutamine echocardiography predicts improvement of hypoperfused dysfunctional myocardium after revascularization in patients with coronary artery disease. Circulation 1995; 91:2556-65.
6. 6. Benotti JR, Grossman W, Braunwald E, et al. Hemodynamic assessment of amrinone: a new inotropic agent. N Engl J Med 1978;299:1373-7.
7. 7. Benotti JR, Grossman W, Braunwald E, Carabello BA. Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure to coronary artery disease. Circulation 1980;62:28-34.
8. 8. Naccarelli GV, Gray EL, Dougherty AH, et al. Amrinone: acute electrophysiologic and hemodynamic effects in patients with congestive heart failure. Am J Cardiol 1984;54:600-4.
9. 9. Hartman A, Saeed M. Phosphodiesterase inhibition in positive inotropic therapy of congestive heart failure. J Appl Cardiol 1986;1:361.
10. 10. Goenen M, Pedemonte O, Baele P, Col J. Amrinone in the management of low cardiac output after open heart surgery. Am J Cardiol 1985;56:33B-38B.
11. 11. Taylor SH, Verma SP, Hussian M, et al. Intravenous amrinone in left ventricular failure complicated by acute myocardial infarction. Am J Cardiol 1985;56:29B-32B.
12. 12. Cragnolino D, DiLeiva A, Masoli O, et al. Viabilidad miocardica: cual es el apremis farmacologico a elegir? Rev Soc Argent Cardiol 1995;63:93-101.
13. 13. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary artery bypass surgery for chronic stable angina. Circulation 1985;72:123.
14. 14. Nesto RW, Kowalchuck GJ. The ischemic cascade: temporal sequence of hemodynamics, electrocardiographic and scintomatic expression of ischemia. Am J Cardiol 1987;59:23C.
15. 15. Bonow RO, Dilsizian V, Cuocolo A, Bacharach SL. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Circulation 1991;83:26-37.
16. 16. Gioia G, Powers J, Heo J, Iskandrian AS, Russel J, Cassel D. Prognostic value of rest-redistribution tomographic thallium-201 imaging in ischemic cardiomyopathy. Am J Cardiol 1995;75:759-62.
17. 17. Dilsizian V, Smeltzer WR, Freedman NMT, Dextras R, Bonow RO. Thallium reinjection after stress-redistribution imaging: does 24-hour delayed imaging after reinjection enhance detection of viable myocardium? Circulation 1991;83:1247-55.
18. 18. Dilsizian V, Freedman NMT, Bacharach SL, Perrone-Filardi P, Bonow RO. Regional thallium uptake in irreversible defects: magnitude of change in thallium activity after reinjection distinguishes viable from nonviable myocardium. Circulation 1992;85:627-34.
19. 19. Dilsizian V, Perrone-Filardi P, Arright JA, et al. Concordance and discordance between stress-redistribution-reinjection and rest-redistribution thallium imaging for assessing viable myocardium: comparison with metabolic activity by positron emission tomography. Circulation 1993;88:941-52.
20. 20. Schelbert HR, Phelps ME, Hoffman E, Huang SC, Kuhl DE. Regional myocardial blood flow, metabolism and function assessed noninvasively with positron emission tomography. Am J Cardiol 1980;80:1269-77.
21. 18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation 1983;67:766-78.
22. 22. Tillisch JH, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884-8.
23. 23. Brunken R, Tillisch J, Schwaiger M, et al. Regional perfusion, glucose metabolism and wall motion in patients with chronic electrocardiographic Q wave infarctions: evidence for persistence of viable tissue in some infarct regions by positron emission tomography. Circulation 1986;73:951-63.
24. 24. Schelbert HR, Buston D. Insights into coronary artery disease gained from metabolic imaging. Circulation 1988;78:496-505.
25. 25. Fudo T, Kambara H, Hashimoto T, et al. F-18 deoxyglucose and stress N-13 ammonia positron emission tomography in anterior wall healed myocardial infarction. Am J Cardiol 1988;61:1191-7.
26. 26. Tamaki N, Yonekura Y, Yamashita K, et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989;64:860-5.
27. 27. Honer Juger P, Shafer-Korting M. Involvement of cydic-AMP in the direct inotropic action of amrinone. Naunyn Schmiedebergs Arch Pharmacol 1981;318:112.
28. 28. Baim DS. Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow. Am J Cardiol 1989;63:23A-6A.
29. 29. Mancini D, LeJemtel T, Sonnenblick E. Intravenous use of amrinone for the treatment of the failing heart. Am J Cardiol 1985;56:8B-15B.
30. 30. Perez Balino N, Masoli O, et al. Test de estimulacion con amrinone: una aproximacion diagnostica para la deteccion de viabilidad miocardica. Rev Soc Argent Cardiol 1992;60:257-68.
31. 31. Jentzer JH, Lejemtel TH, Sonnenblick EH, Kirk ES. Beneficial effect of amrinone on myocardial oxygen consumption during acute left ventricular failure in dogs. Am J Cardiol 1981;48:75-81.
32. m) cyclic adenosine monophosphate phosphodiesterase. Am J Cardiol 1989;63:2A-8A.
33. 33. Kaul S. There may be more to viability than meets the eye! Circulation 1995;92:2790-3.
34. 34. Kaul S. Response of dysfunctional myocardium to dobutamine. J Am Cardiol 1996;27:1608-11.
35. 35. Elhendy A, Cornel JH, Roelandt JRTC, et al. Relation between contractile response of akinetic segments during dobutamine stress echocardiography and myocardial ischemia assessed by simultaneous thallium-201 single photon emission computed tomography. Am J Cardiol 1996;77:955-9.